Dunlavin was alive with the sounds of music and song when the community came together at St Nicholas Church of Ireland for a ...

Kyle Bryant was diagnosed with Friedreich's Ataxia, or FA, at 17 years old. Friedreich's Ataxia is a a rare neuromuscular disease that affects 1 in 50,000 people. Over the last ...

When he was 19, he was halfway through a tattoo apprenticeship when he was diagnosed with Friedreich's Ataxia (FA)—a degenerative neuromuscular disorder that's debilitating and life-shortening.

Citi says a share overhang has been removed after Larimar Therapeutics (LRMR) announced it has received FDA alignment on an accelerated ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $19 and keeps an Outperform rating on the shares. The firm ...

Anthony Monaco was a very active teen—involved in soccer, wrestling, and even cross country—but he always felt a little awkward physically. It started with running a little differently than the kids ...

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Learn more about whether Alvotech or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.